Cellular Immunotherapy for Hematological Malignancy and Solid Tumor is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy for Hematological Malignancy and Solid Tumor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular Immunotherapy for Hematological Malignancy and Solid Tumor overview
Cellular therapy is under development for the treatment of hematological malignancies including multiple myeloma, lymphoma, and chronic lymphocytic leukemia and solid tumors including squamous cell carcinoma, ovarian cancer, bladder cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It is administered through intravenous route. It comprises of ex vivo activated autologous peripheral blood mononuclear cells (PBMC).
Alloplex Biotherapeutics overview
Alloplex Biotherapeutics., is a biotechnology company developing an off-the-shelf anti-tumor vaccine. The company is headquartered in United States.
For a complete picture of Cellular Immunotherapy for Hematological Malignancy and Solid Tumor’s drug-specific PTSR and LoA scores, buy the report here.